EU Getting Left Behind On Drug Review Times
EU Review Times Aren't So Much Lagging As Other Agencies Are Improving
Executive Summary
Drug review times in the EU are not getting slower but other agencies are getting faster. A pharmaceutical industry representative offers some frank advice on how the EU can stay competitive.
You may also be interested in...
EU ‘Big Data’ Report: Big Opportunities – And Big Challenges
EU regulators have produced the first fruits of their ambitious “big data” project aimed at ensuring that the EU drug regulatory system can make full use of the rapidly increasing volume and complexity of data being gathered across multiple settings in the healthcare area.
Wait For Benefits Of EudraVigilance Pilot Before Expanding To More EU Products, Says Pharma
Drug companies say that any decision on taking the EudraVigilance monitoring requirements into the next phase should only be made when there is clear evidence that it has improved patient safety.
EMA Wants Stakeholder Input On Regulatory Challenges To 2025
The EMA has launched a six-month consultation on the challenges facing the agency and the wider EU regulatory network in the face of emerging scientific and technological advances, and has put forward a range of recommendations for action in the period to 2025 to ensure the regulatory system is fit for purpose.